US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.26 — a miss of 34.6%.
Analysts rate Janux Therapeutics Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $36.24.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 18.30% |
| BlackRock Inc | 8.89% |
| HHG PLC | 6.86% |
| Prosight Management, LP | 6.22% |
| FMR Inc | 4.15% |
| State Street Corp | 4.03% |
| Federated Hermes Inc | 3.85% |
| Vanguard Capital Management, LLC | 2.96% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 JANUX THERAPEUTICS, INC. – FORM 10-Q SUMMARY For Quarterly Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and equivalents: $27.8 million (d | 2026-08-06 |
| Results announced · Q3 2026 JANUX THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash and short-term investments: $970.9 million as of June 30, 2026 (vs. $96 | 2026-08-06 |
| Company announcement · Q2 2026 JANUX THERAPEUTICS, INC. - 8-K SUMMARY OTHER NOTABLE POINTS • Chief Medical Officer William Go, M.D., Ph.D. departed the company on June 23, 2026 un | 2026-06-23 |
| Shareholder vote results · Q2 2026 JANUX THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Record date for 2026 Annual Meeting: April 17, 2026 • Total shares outstanding and entitle | 2026-06-12 |
| Quarterly report · Q1 2026 JANUX THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Assets: $1,028.2 million as of March 31, 2026 (up from $1,001.6 million at | 2026-05-07 |
| Results announced · Q2 2026 JANUX THERAPEUTICS Q1 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Cash and short-term investments: $956.4 million (March 31, 2026) vs. $966.6 million | 2026-05-07 |
| Proxy statement · Q2 2026 JANUX THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGE • CEO David Campbell's total compensation for fiscal 2025: No | 2026-04-28 |
| Annual report FY2025 JANUX THERAPEUTICS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Public company: Janux Therapeutics, Inc., ticker JANX, traded on Nas | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Janux Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.